Mobile

A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Cl...

Update Il y a 5 ans
Reference: EUCTR2009-013053-15

A Phase II Open Label Study of MK-7009 Administered Concomitantly with Pegylated Interferon Alfa-2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

In patients who have persistent HCV infection after prior participation in a MK-7009 clinical trial: Evaluate the safety and tolerability of MK-7009 600 mg b.i.d. for 48 weeks when used in combination with peg-IFN alfa-2a and RBV.

Inclusion criteria

  • HEPATITIS C VIRUS

Links